Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

40.65
+2.245.83%
Post-market: 40.10-0.5500-1.35%19:59 EDT
Volume:728.83K
Turnover:29.43M
Market Cap:297.75M
PE:-0.23
High:41.77
Open:38.11
Low:38.06
Close:38.41
Loading ...

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

THOMSON REUTERS
·
09 Apr

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

GlobeNewswire
·
09 Apr

Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects

TIPRANKS
·
07 Apr

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

GlobeNewswire
·
07 Apr

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

GlobeNewswire
·
01 Apr

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

ACCESS Newswire
·
31 Mar

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

ACCESS Newswire
·
29 Mar

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

GlobeNewswire
·
27 Mar

Tonix Pharmaceuticals Shares Jump After FDA Guidance for TNX-102

Dow Jones
·
24 Mar

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires Live
·
24 Mar

Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment

MT Newswires Live
·
24 Mar

Tonix Pharmaceuticals Holding Corp - Commercial Planning for Tnx-102 Sl Launch in Q4 2025 Underway

THOMSON REUTERS
·
24 Mar

Tonix Pharmaceuticals Holding Corp - FDA Pdufa Goal Date for Tnx-102 Sl Set for August 15, 2025

THOMSON REUTERS
·
24 Mar

Tonix Pharmaceuticals Announces That FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Tnx-102 Sl for the Management of Fibromyalgia

THOMSON REUTERS
·
24 Mar

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

GlobeNewswire
·
24 Mar

Tonix Pharmaceuticals Price Target Maintained With a $70.00/Share by Noble Capital Markets

Dow Jones
·
21 Mar

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

ACCESS Newswire
·
20 Mar

Tonix Pharmaceuticals Reports 2024 Financial Results and Pipeline Progress

TIPRANKS
·
19 Mar

Tonix Pharmaceuticals Shares Fall on Lower 4Q Revenue, Net Loss

Dow Jones
·
19 Mar

Tonix Pharmaceuticals Q4 2024 GAAP EPS $(9.77) Beats $(291.74) Estimate, Sales $2.600M Miss $3.500M Estimate

Benzinga
·
19 Mar